Chiron Issues Fourth Quarter, Full-Year Earnings Restatement
This article was originally published in The Pink Sheet Daily
Executive Summary
The restatement is the result of improper revenue recognition of traveler vaccines in the second quarter and later periods, Chiron says. The company also reports lower flu vaccine sales as part of the restatement.
You may also be interested in...
Justice Department Opens Investigation Into Fluvirin
Chiron is responding to a grand jury subpoena from the New York City U.S. Attorney's Office regarding Fluvirin
HHS Team Heads To England To Analyze Fluvirin Data
CBER Director Jesse Goodman will lead team in discussions with the U.K. regulatory agency. HHS Secretary Thompson hopes to secure a partial release of Fluvirin doses following suspension of Chiron’s license to manufacture influenza vaccine for three months.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.